@article{b7614d1ddbdc4a91a95f34008f1dd1b2,
title = "Adnexal mass risk assessment: A multivariate index assay for malignancy risk stratification",
abstract = "Aims: Adnexal mass risk assessment (AMRA) stratifies patients with adnexal masses, identifying the relatively small number of malignancies from benigns which might take a 'watchful waiting' approach. Methods: AMRA uses seven biomarkers and derived from women with adnexal masses scheduled for surgery. Estimated clinical performance was calculated using fixed prevalence. Results: At 5% prevalence, the high-risk group, 7.9% total, captured 75.9% of invasive malignancies at a positive predictive value of 35.8%. High risk/intermediate risk combined had a sensitivity of 89.7 and 95.6% for pre- and post-menopausal cancers, respectively. The low-risk group, 67.8% total, had an negative predictive value of 99.0%. Conclusion: With highly differentiating risk stratification capability across histological subtypes and stages, AMRA is potentially applicable to patients with adnexal masses to assist deciding whether immediate surgery is recommended.",
keywords = "adnexal mass, multivariate index assay, ovarian cancer, watch and wait",
author = "Zhen Zhang and Bullock, {Rowan G.} and Herbert Fritsche",
note = "Funding Information: This research and manuscript were funded by Vermillion, Inc. Herbert Fritsche is an employee of ASPiRA Labs, a subsidiary of Vermillion, Inc. Rowan G Bullock is an employee of Vermillion, Inc. Zhen Zhang is a consultant with Vermillion, Inc., however contributed to this work in a personal capacity and is independent of his affiliation with Johns Hopkins University. Vermillion, Inc. provided funding for this study. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Funding Information: This research and manuscript were funded by Vermillion, Inc. Herbert Fritsche is an employee of ASPiRA Labs, a subsidiary of Vermillion, Inc. Rowan G Bullock is an employee of Vermillion, Inc. Zhen Zhang is a consultant with Vermillion, Inc., however contributed to this work in a personal capacity and is independent of his affiliation with Johns Hopkins University. Vermillion, Inc. provided funding for this study. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2019 Rowan Bullock.",
year = "2019",
doi = "10.2217/fon-2019-0479",
language = "English (US)",
volume = "15",
pages = "3783--3795",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "33",
}